poisar

Stocks · News reference

Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $276

BenzingaJul 29, 2026, 6:16 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 29, 2026, 6:16 PM
Checked
Jul 29, 2026, 6:16 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 5, 2026, 4:30 AMHealthcare Foresights

    [Latest] Global eClinical Solutions Market Size/Share Worth USD 42.55 Billion by 2035 at a 13.98% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

    The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.

    Read original at globenewswire-inc
  2. The Motley FoolAug 2, 2026, 7:31 PMJonathan Ponciano

    An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

    IQVIA CEO Ari Bousbib sold approximately 106,000 shares worth $26.1 million through an exercise-and-sell of expiring stock appreciation rights. The sale follows a strong Q2 earnings report with record clinical bookings of $3.15 billion and 8.7% revenue growth. Bousbib maintains a substantial 1.4 million share position, indicating the sale was routine calendar management rather than a bearish signal.

    Read original at the-motley-fool